MiMedx to Present at the 39th Annual J.P. Morgan Healthcare Conference
MARIETTA, Ga., Dec. 07, 2020 - MiMedx Group, Inc. (Nasdaq: MDXG) will present at the 39th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MARIETTA, Ga., Dec. 07, 2020 - MiMedx Group, Inc. (Nasdaq: MDXG) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 4:30 PM EST. The company, known for its advanced wound care solutions, invites institutional investors to connect with management through J.P. Morgan representatives. A live webcast can be accessed on the company's website, with a replay available post-presentation. MiMedx specializes in human placental tissue allografts and has supplied over two million allografts using its proprietary processes.
Details
News Market Reaction – MDXG
The recorded move for MDXG in the trading session of this news was -2.91%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MARIETTA, Ga., Dec. 07, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that management will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13th at 4:30 PM EST. Institutional investors interested in meeting with management during the conference may reach out to their J.P. Morgan representative.
A webcast of the presentation will be available on the Events page of the Investors section of the Company’s website. A replay of the webcast will be available on the Company’s website at www.mimedx.com following the conclusion of the presentation.
About MiMedx
MiMedx® is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied more than two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.
Contacts:
Investors
Jack Howarth
404-360-5681
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.